Outcome prediction by immunophenotypic minimal residual disease detection in adult T‐cell acute lymphoblastic leukaemia
Mauro Krampera(University of Verona), Giovanni Pizzolo(Fondazione IRCCS Istituto Nazionale dei Tumori), C. Vincenzi(University of Verona), Andrea Camera(Radboud University Nijmegen), Richard Szydlo(Imperial College London), Francesco Nobile(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Luciana Annino(Sapienza University of Rome), Giuseppe Fioritoni, Anna Guarini(Sapienza University of Rome), Francesco Fabbiano(San Antonio College), Antonella Vitale(University of the Sacred Heart), Franco Mandelli(San Antonio College), Omar Perbellini(University of Verona), Giuseppe Todeschini(University of Pisa), Robin Foà(Sapienza University of Rome)
Cited by 66
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644